NCT05483712 is a NA clinical trial of Brass Mesh Bolus in Breast Cancer, sponsored by Nova Scotia Cancer Centre.

Who is sponsoring NCT05483712?

NCT05483712 is sponsored by Nova Scotia Cancer Centre.

What drugs are being tested in NCT05483712?

Interventions in NCT05483712: Brass Mesh Bolus.

What condition does NCT05483712 study?

NCT05483712 studies Breast Cancer.

Is NCT05483712 still recruiting?

NCT05483712 is currently recruiting now. Last updated 22 May 2024.

Last reviewed 2024-05-22 · How we verify

NCT05483712

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brass Mesh Bolus in Rotational Post-Mastectomy Radiation Therapy

Recruiting now NA Last updated 22 May 2024

What this trial tests

NA trial testing Brass Mesh Bolus in Breast Cancer in 20 participants. Currently enrolling.

Timeline

18 January 2023

Primary endpoint
21 November 2024

21 November 2024

Quick facts

Lead sponsor	Nova Scotia Cancer Centre
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	18 January 2023
Primary completion	21 November 2024
Estimated completion	21 November 2024
Sites	1 location across Canada

Drugs / interventions tested

Brass Mesh Bolus

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Nova Scotia Cancer Centre — full company profile →

Who can join

Eligibility, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis is that the daily use of brass mesh bolus achieves a comparable dose to every-other-day use of Superflab bolus (current standard of care) in chest wall post-mastectomy patients treated with rotational 6 MV photon delivery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Effects of Radiotherapy on the Sequence and Eligibility of Breast Reconstruction: Current Evidence and Controversy.
Campbell AR, Didier AJ, Sheikh TM, Ansari S, et al · · 2024 · cited 4× · PMID 39272797 · DOI 10.3390/cancers16172939

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483712 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Cancer Centre
Last refreshed: 22 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing